Atavistik Bio Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
37
- Latest Deal Type
-
Series B1
- Latest Deal Amount
-
$40M
- Investors
-
6
Atavistik Bio General Information
Description
Operator of a biopharmaceutical company intended to focus on the discovery and development of novel therapies for metabolic diseases and cancer. The company's platform maps metabolite protein interactions and analyzes cellular pathways through quantitative biochemical assays, computational modeling, and high-throughput screening workflows, enabling pharmaceutical and biotechnology organizations to identify novel drug targets, generate mechanistically informed therapeutic candidates, and evaluate biological relevance with greater precision.
Contact Information
Website
www.atavistikbio.comCorporate Office
- 101 Cambridgepark Drive
- 3rd floor
- Cambridge, MA 02140
- United States
Corporate Office
- 101 Cambridgepark Drive
- 3rd floor
- Cambridge, MA 02140
- United States
Atavistik Bio Timeline
Atavistik Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC (Series B1) | 03-Feb-2026 | $40M | Completed | Clinical Trials - Phase 1 | ||
| 3. Early Stage VC (Series B) | 18-Dec-2025 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 19-Dec-2023 | $100M | $100M | Completed | Clinical Trials - Phase 1 | |
| 1. University Spin-Out | 01-Jan-2021 | Completed | Startup |
Atavistik Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-1 | ||||||||
| Series B | ||||||||
| Series A | 103,336,982 | $0.000010 | $0.08 | $1 | $1 | 1x | $1 | 28.51% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Atavistik Bio Comparisons
Industry
Financing
Details
Atavistik Bio Competitors (54)
One of Atavistik Bio’s 54 competitors is Aulos, a Venture Capital-Backed company based in Larkspur, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aulos | Venture Capital-Backed | Larkspur, CA | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Xenetic Biosciences | Corporation | Framingham, MA | ||||
| ArriVent Biopharma | Formerly VC-backed | Newtown Square, PA | ||||
| Bright Peak Therapeutics | Venture Capital-Backed | Allschwil, Switzerland |
Atavistik Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Atavistik Bio Patents
Atavistik Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026198909-A2 | Jak2 inhibitors and methods of use thereof | Pending | 21-Mar-2025 | ||
| WO-2026198909-A3 | Jak2 inhibitors and methods of use thereof | Pending | 21-Mar-2025 | ||
| WO-2026193420-A1 | Substituted aminopyridine compounds and methods of treating disease using the same | Pending | 14-Mar-2025 | ||
| WO-2026193443-A1 | Substituted aminopyridine compounds, derivatives, and methods of treating disease using the same | Pending | 14-Mar-2025 | ||
| WO-2026193445-A1 | Substituted aminopyridine compounds, derivatives, and methods of treating disease using the same | Pending | 14-Mar-2025 | C07D471/04 |
Atavistik Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Atavistik Bio Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| RA Capital Management | Asset Manager | Minority | ||
| Regeneron Ventures | Corporate Venture Capital | Minority | ||
| Lux Capital | Venture Capital | Minority | ||
| Nextech Invest | Venture Capital | Minority | ||
| The Column Group | Venture Capital | Minority |
Atavistik Bio FAQs
-
When was Atavistik Bio founded?
Atavistik Bio was founded in 2021.
-
Where is Atavistik Bio headquartered?
Atavistik Bio is headquartered in Cambridge, MA.
-
What is the size of Atavistik Bio?
Atavistik Bio has 37 total employees.
-
What industry is Atavistik Bio in?
Atavistik Bio’s primary industry is Drug Discovery.
-
Is Atavistik Bio a private or public company?
Atavistik Bio is a Private company.
-
What is the current valuation of Atavistik Bio?
The current valuation of Atavistik Bio is .
-
What is Atavistik Bio’s current revenue?
The current revenue for Atavistik Bio is .
-
How much funding has Atavistik Bio raised over time?
Atavistik Bio has raised $299M.
-
Who are Atavistik Bio’s investors?
RA Capital Management, Regeneron Ventures, Lux Capital, Nextech Invest, and The Column Group are 5 of 6 investors who have invested in Atavistik Bio.
-
Who are Atavistik Bio’s competitors?
Aulos, Ayala Pharmaceuticals, Xenetic Biosciences, ArriVent Biopharma, and Bright Peak Therapeutics are some of the 54 competitors of Atavistik Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
